Further, as cancer cells with hyperactive mTORC1, either due to loss of PTEN or TSC1/2, have been shown to be particularly sensitive to rapamycin treatment [46],[47], we speculate that cancer cells with mutated NPRL2 might also be particularly sensitive to rapamycin. This evidence concerns the gene NPRL2 and cancer.